Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02257528 · ClinicalTrials.gov registry record · Phase 2
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 20
- Study locations
NCT02257528 is a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants, below the 122-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT02257528, a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Nivolumab
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Regional Hospital - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
California
- Sutter Auburn Faith Hospital - Auburn
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Mills-Peninsula Medical Center - Burlingame
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- Eden Hospital Medical Center - Castro Valley
- Sutter Davis Hospital - Davis
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Arkansas
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-05-18 |
| Est. Completion | 2026-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02257528
The ClinicalTrials.gov registry entry for NCT02257528 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (79% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cervical Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02257528 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alaska, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT02257528 about?
NCT02257528 is a clinical study titled "Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer". This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
What is the current status of trial NCT02257528?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2015-05-18. Estimated completion is 2026-03-17.
What conditions does trial NCT02257528 study?
This clinical trial studies the following conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7.
What interventions are being tested in trial NCT02257528?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02257528?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02257528 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
COMPLETED · Phase 2
-
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
COMPLETED · Phase 2
-
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.